Remove Acquisitions Remove Mergers and Acquisitions Remove Pharmaceutical
article thumbnail

Delaware Law Alert: Chancery Court Applies Conditional Probability to Calculate Damages in Earnout Dispute

JD Supra: Mergers

The case arose from Alexion Pharmaceuticals, Inc.’s s 2018 acquisition of Syntimmune, Inc. A recent Delaware Chancery Court opinion offers a significant example of how courts may apply complex probability analysis to determine the amount of damages in an earnout dispute.

article thumbnail

Mergers and Acquisitions in the Age of Trump: Opportunities and Challenges

MergersCorp M&A International

His presidency brought with it a unique set of policies and attitudes that would directly influence the realm of mergers and acquisitions (M&A). These regulatory rollbacks naturally benefitted companies considering mergers and acquisitions. Foreign companies sought to acquire U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

While global M&A deal value across sectors remained relatively flat overall , pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. Indeed, the largest US biotech exit in 2024 was Vertex Pharmaceuticals $4.9 Total deal value is where the market really shed its weight down a remarkable 33.7%

M&A
article thumbnail

Healthcare & Life Sciences Private Equity Deal Tracker: Great Point Acquires Eutecma

JD Supra: Mergers

Great Point Partners (GPP) has announced the acquisition of a majority stake in Eutecma. Eutecma, founded in 2008 and based in Germany, is a developer of temperature-controlled packaging solutions for pharmaceutical cold chain shipments. By: McGuireWoods LLP

article thumbnail

New UK Competition Rules to Impact Global Deal Reviews for Tech and Pharma

JD Supra: Mergers

The UK DMCC forms part of a global trend to focus merger review increasingly on vertical concerns and concerns about eliminating nascent competition, including by so-called “killer acquisitions” of firms perceived as future competitive threats. The reforms are particularly relevant to the technology and pharmaceutical.

article thumbnail

Energy & Sustainability M&A Activity — September 2024

JD Supra: Mergers

August 01, 2024: SEAM Group, a B2B business products and services company that provides safety, reliability, maintenance, and enterprise asset management services in the hospitality, food processing, and pharmaceutical industries, was acquired by ABB for an undisclosed amount.

M&A
article thumbnail

Boston Scientific to Acquire Axonics for $3.7 Billion

JD Supra: Mergers

Morgan Healthcare Conference in San Francisco, which also saw the announcement of major acquisitions by large players in the pharmaceutical space. The timing of the announcement coincided with the start of the 42nd Annual J.P. By: Knobbe Martens